Physician profile
Peter J Casella
NPI 1245200278
$17,228.28
in general payments reported to CMS, 2019-2025
31 companies · $42.49 in 2025
The $42.49 reported for 2025 was less than what a typical Obstetrics & Gynecology provider received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $979 · 2020: $1,450 · 2021: $3,600 · 2022: $11K · 2023: $26.57 · 2024: $52.25 · 2025: $42.49.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $121.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $121.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $10,530.60 | 2022 | |
| Abbvie INC. | $2,625.16 | 2019-2022 | |
| Minerva Surgical, INC | $1,072.46 | 2020-2024 | |
| Olympus Corporation of The Americas | $698.22 | 2021 | |
| Hologic Sales and Service, LLC | $417.54 | 2021-2022 | |
| Therapeuticsmd, INC. | $216.33 | 2019-2022 | |
| Vertical Pharmaceuticals, LLC | $210.60 | 2019 | |
| Meditrina | $160.56 | 2019-2022 | |
| Merz North America, INC. | $149.31 | 2019 | |
| Bard Access Systems, INC. | $140.35 | 2019 | |
| Roche Diagnostics Corporation | $106.82 | 2020 | |
| Pacira Pharmaceuticals Incorporated | $100.00 | 2019 | |
| Gynesonics, INC. | $93.15 | 2021 | |
| Allotrope Medical, INC | $79.33 | 2021 | |
| Myovant Sciences INC. | $77.93 | 2021-2022 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ibsa Pharma INC. | $68.80 | 2019-2022 | |
| Millicent US INC | $60.54 | 2019-2022 | |
| Channel Medsystems, INC. | $58.88 | 2022 | |
| Pfizer INC. | $58.12 | 2022 | |
| Astellas Pharma US INC | $52.00 | 2022-2024 | Veozah |
| Lupin INC. | $48.47 | 2019-2020 | |
| Mimedx Group, INC. | $42.49 | 2025 | |
| Avion Pharmaceuticals | $42.24 | 2022-2023 | Divigel |
| Ascend Therapeutics US, LLC | $24.88 | 2022 | |
| Evofem Biosciences, INC. | $19.64 | 2022 | |
| Biohaven Pharmaceuticals, INC. | $18.10 | 2021 | |
| Allergan, INC. | $16.46 | 2019 | |
| Dysis Medical, INC. | $13.28 | 2019 | |
| Olympus America INC. | $13.19 | 2021 | |
| Sumitomo Pharma America, INC. | $12.83 | 2023 | Myfembree |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Peter Casella listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.